Raymond Yurko

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Nicholas J. Izzo, Jinbin Xu, Chenbo Zeng et al. · PLoS ONE · 2014 · 303 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Nicholas J. Izzo, Agnes Staniszewski, Lillian K. To et al. · PLoS ONE · 2014 · 187 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera et al. · Alzheimer s & Dementia · 2021 · 103 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction

Maliha Zahid, Kyle S. Feldman, Gabriel Garcia-Borrero et al. · Biomolecules · 2018 · 59 citations · Full text

Medicine, Pharmaceutics, Pharmacology +17

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease

Gilbert M. Rishton, Gary C. Look, Zhi‐Jie Ni et al. · ACS Medicinal Chemistry Letters · 2021 · 41 citations · Full text

Medicine, Neuroscience, Pharmacology +17